Cerebral dopamine neurotrophic factor improves long-term memory in APP/PS1 transgenic mice modeling Alzheimer's disease as well as in wild-type mice

Behavioural Brain Research

Volumn 291, Issue , 2015, Pages 1-11

  Kemppainen, Susanna ^a   Lindholm, Päivi ^b   Galli, Emilia ^b   Lahtinen, Hanna Maija ^a   Koivisto, Henna ^a   Hämäläinen, Elina ^a   Saarma, Mart ^b   Tanila, Heikki ^a,c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Amyloid; Gene therapy; Memory; Neurotrophic factor; Transgenic

Indexed keywords

ADENOVIRUS VECTOR; AMYLOID BETA PROTEIN; NEUROTROPHIC FACTOR; RECOMBINANT CEREBRAL DOPAMINE NEUROTROPHIC FACTOR; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; AMYLOID; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; CDNF PROTEIN, HUMAN; NERVE GROWTH FACTOR; PRESENILIN 1; PSEN1 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BRAIN LEVEL; CONTROLLED STUDY; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; GENE THERAPY; LEARNING AND MEMORY TEST; LONG TERM MEMORY; MOUSE; NEOPHOBIA; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; SPATIAL LEARNING; TRANSGENE; TRANSGENIC MOUSE; TREATMENT RESPONSE; ANIMAL; C3H MOUSE; C57BL MOUSE; DEPENDOPARVOVIRUS; DISEASE MODEL; GENE VECTOR; GENETICS; HIPPOCAMPUS; HUMAN; MEMORY CONSOLIDATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PSYCHOLOGY;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HIPPOCAMPUS; HUMANS; MEMORY CONSOLIDATION; MEMORY, LONG-TERM; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; NERVE GROWTH FACTORS; NEUROGENESIS; PRESENILIN-1; RECOMBINANT PROTEINS;

EID: 84929579664     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.05.002     Document Type: Article

References (31)

1. Michalski B., Fahnestock M. Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer's disease. Mol Brain Res 2003, 111(1-2):148-154.
2. Peng S., Wuu J., Mufson E.J., Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem 2005, 93(6):1412-1421.
3. Fahnestock M., Michalski B., Xu B., Coughlin M.D. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol Cell Neurosci 2001, 18(2):210-220.
4. Airavaara M., Pletnikova O., Doyle M.E., Zhang Y.E., Troncoso J.C., Liu Q.-R. Identification of novel GDNF isoforms and cis-antisense GDNFOS gene and their regulation in human middle temporal gyrus of Alzheimer disease. J Biol Chem 2011, 286(52):45093-45102.
5. Nagahara A.H., Merrill D.A., Coppola G., Tsukada S., Schroeder B.E., Shaked G.M., et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 2009, 15(3):331-337.
6. Fischer W., Wictorin K., Björklund A., Williams L.R., Varon S., Gage F.H. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 1987, 329(6134):65-68.
7. Lee Y.-S., Danandeh A., Baratta J., Lin C.-Y., Yu J., Robertson R.T. Neurotrophic factors rescue basal forebrain cholinergic neurons and improve performance on a spatial learning test. Exp Neurol 2013, 249:178-186.
8. Tuszynski M.H., Thal L., Pay M., Salmon D.P., U H.S., Bakay R., et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005, 11(5):551-555.
9. Revilla S., Ursulet S., Alvarez-López M.J., Castro-Freire M., Perpiñá U., García-Mesa Y., et al. Lenti-GDNF gene therapy protects against Alzheimer's disease-like neuropathology in 3xTg-AD mice and MC65 cells. CNS Neurosci Ther 2014, 20(11):961-972.
10. Bäck S., Peränen J., Galli E., Pulkkila P., Lonka-Nevalaita L., Tamminen T., et al. Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease. Brain Behav 2013, 3(2):75-88.
11. Lindholm P., Voutilainen M.H., Laurén J., Peränen J., Leppänen V.-M., Andressoo J.-O., et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 2007, 448(7149):73-77.
12. Airavaara M., Harvey B.K., Voutilainen M.H., Shen H., Chou J., Lindholm P., et al. CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. Cell Transplant 2012, 21(6):1213-1223.
13. Lindahl M., Danilova T., Palm E., Lindholm P., Võikar V., Hakonen E., et al. MANF is indispensable for the proliferation and survival of pancreatic β cells. Cell Rep 2014, 7(2):366-375.
14. Garcia-Alloza M., Robbins E.M., Zhang-Nunes S.X., Purcell S.M., Betensky R.A., Raju S., et al. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 2006, 24(3):516-524.
15. Minkeviciene R., Ihalainen J., Malm T., Matilainen O., Keksa-Goldsteine V., Goldsteins G., et al. Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J Neurochem 2008, 105(3):584-594.
16. Aizenstein H.J., Nebes R.D., Saxton J.A., Price J.C., Mathis C.A., Tsopelas N.D., et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008, 65(11):1509-1517.
17. Kadir A., Almkvist O., Forsberg A., Wall A., Engler H., Långström B., et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging 2012, 33(1):198e1-198e14.
18. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013, 12(2):207-216.
19. Wang J., Tanila H., Puoliväli J., Kadish I., van Groen T. Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol Dis 2003, 14(3):318-327.
20. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 2004, 13(2):159-170.
21. Da Silva W.C., Köhler C.C., Radiske A., Cammarota M. D1/D5 dopamine receptors modulate spatial memory formation. Neurobiol Learn Mem 2012, 97(2):271-275.
22. Ambrée O., Richter H., Sachser N., Lewejohann L., Dere E., de Souza Silva M.A., et al. Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer's disease. Neurobiol Aging 2009, 30(8):1192-1204.
23. Liu Y., Yoo M.J., Savonenko A., Stirling W., Price D.L., Borchelt D.R., et al. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J Neurosci 2008, 28(51):13805-13814.
24. Hellman M., Arumäe U., Yu L., Lindholm P., Peränen J., Saarma M., et al. Mesencephalic astrocyte-derived neurotrophic factor (MANF) has a unique mechanism to rescue apoptotic neurons. J Biol Chem 2011, 286(4):2675-2680.
25. Klann E., Dever T.E. Biochemical mechanisms for translational regulation in synaptic plasticity. Nat Rev Neurosci 2004, 5(12):931-942.
26. Lindholm P., Saarma M. Novel CDNF/MANF family of neurotrophic factors. Dev Neurobiol 2010, 70(5):360-371.
27. Kemppainen S., Rantamäki T., Jerónimo-Santos A., Lavasseur G., Autio H., Karpova N., et al. Impaired TrkB receptor signaling contributes to memory impairment in APP/PS1 mice. Neurobiol Aging 2012, 33(6). 1122.e23-39.
28. Rantamäki T., Kemppainen S., Autio H., Stavén S., Koivisto H., Kojima M., et al. The Impact of Bdnf gene deficiency to the memory impairment and brain pathology of APPswe/PS1dE9 mouse model of Alzheimer's disease. PLoS ONE 2013, 8(7):e68722.
29. Irizarry M.C., McNamara M., Fedorchak K., Hsiao K., Hyman B.T. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 1997, 56(9):965-973.
30. Puli L., Pomeshchik Y., Olas K., Malm T., Koistinaho J., Tanila H. Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease. J Neuroinflammation 2012, 9:105.
31. Verret L., Jankowsky J.L., Xu G.M., Borchelt D.R., Rampon C. Alzheimer's-type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hippocampal neurogenesis. J Neurosci 2007, 27(25):6771-6780.